What's New: Drugs RSS Feed

Articles · 12

• FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves axatilimab-csfr for chronic graft-versus-host disease

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves durvalumab for limited-stage small cell lung cancer

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma

  Medicine · Nov 7, 2026 · Original ↗

• FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer

  Medicine · Nov 7, 2026 · Original ↗